secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-280141
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla Q3 net loss $15.8M; FDA aligns on Phase 3 Oz-V design; partnership on track by year-end
--------------------------------------------------------------------------------

- Q3 2025 net loss $15.8M vs $10.6M in 2024 (which included $11M Context collaboration revenue); cash $8.3M at Sept 30.
- FDA alignment achieved on Phase 3 Oz-V trial for 2L+ OPSCC; dual primary endpoints (ORR and OS) with potential accelerated approval.
- Company in advanced stages to finalize a strategic transaction by year-end; Context milestone payment of $2M received.
- BA3182 (CAB-EpCAM x CD3 TCE) Phase 1 dose escalation ongoing; readout expected in first half 2026.
- R&D expenses decreased to $9.5M from $16.4M due to program prioritization and workforce reduction in March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000119312525280141/0001193125-25-280141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000119312525280141/bcab-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-280141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer